Smoking Cessation Assistance for Patients With Bladder Cancer: A National Survey of American Urologists

Bjurlin, Marc A.; Goble, Sandra; Hollowell, Courtney M.P.

doi:10.1016/j.juro.2010.06.140

Cited by 74 publications

(61 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 The findings of our study initiated a quality initiative at our institution in which we reviewed patient charts in kidney and bladder cancer clinics and discovered less than half of current smokers were referred to smoking cessation programs; however, more than two thirds of patients who were referred did follow up with their appointment. The diagnosis of cancer and discussion of treatment presents an excellent opportunity to encourage smoking cessation among patients.…”

Section: Discussionmentioning

confidence: 97%

Comprehensive Assessment of the Impact of Cigarette Smoking on Survival of Clear Cell Kidney Cancer

et al. 2014

View full text Add to dashboard Cite

Purpose Despite recent reports describing an association between smoking exposure and kidney cancer stage at diagnosis, the impact of smoking on cancer-specific outcomes is understudied. We evaluated the impact of smoking exposure on cancer-specific death in patients with clear cell renal cell carcinoma (ccRCC) treated with surgery. Materials and Methods Patient and disease characteristics from 1,625 patients with nonmetastatic ccRCC treated with partial or radical nephrectomy between 1995 and 2012 were collected from a prospectively maintained database at Memorial Sloan-Kettering Cancer Center. The associations between smoking status and both advanced disease (American Joint Committee on Cancer stage >2) and cancer-specific death were determined. Results The prevalence rates of current, former, and never smoking at diagnosis were 16%, 30%, and 54%, respectively, and 62.4% of patients reported a ≥20 pack-year smoking history. With a median follow-up period among survivors of 4.5 years (IQR 2.2–7.9), 19.5% (n=316) died during follow-up, 108 (34%) due to disease. We demonstrated ≥20 pack-year smoking history was associated with a significantly increased risk for advanced disease (American Joint Committee on Cancer stage > 2) on logistic regression (odds ratio 1.43, 95% confidence interval 1.02–2.00). Although pathologic stage and Fuhrman grade adversely affected the likelihood of cancer-specific death, smoking status was not associated with cancer-specific death in multivariable competing risks analysis (p=0.29). However, current smokers faced a significantly higher risk for death from other causes as compared with never smokers (hazard ratio 1.93, 95% confidence interval 1.29–2.88). Conclusions Patients with heavy smoking exposure histories presented with more advanced ccRCC. Although smoking status at diagnosis and cumulative smoking exposure were not associated with ccRCC-specific death, our findings suggest that smoking exposure increases risk for death from other causes in patients with ccRCC. Treatment plans to promote smoking cessation are recommended for these patients.

show abstract

Section: Discussionmentioning

confidence: 97%

Comprehensive Assessment of the Impact of Cigarette Smoking on Survival of Clear Cell Kidney Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Urologists are in an important position to encourage patients to quit smoking [27][28][29][30] and decrease the risk of bladder and kidney cancer, and erectile dysfunction. Relatively inexpensive interventions to promote smoking cessation can decrease the likelihood of these conditions or decrease the chance of recurrence.…”

Section: Discussionmentioning

confidence: 99%

Ethnicity and Smoking Status are Associated with Awareness of Smoking Related Genitourinary Diseases

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…At the patient level, barriers include feelings of shame, helplessness, depression and anxiety symptoms, perceived importance of quitting, and level of nicotine addiction (Simmons et al, 2013; Leone et al, 2013; Coups, Dhingra, Heckman et al, 2009). Physician barriers also exist, including physicians' training around smoking cessation, referral options, and beliefs about patients' interest or ability to quit (Toll et al, 2013; Leone et al, 2013; Bjurlin, Goble, & Hollowell, 2010; Patsakham, Ripley-Moffitt, & Goldstein, 2009). At the healthcare system level, inadequate identification of tobacco users, lack of integrated smoking cessation programs, and lack of dedicated tobacco cessation staff all contribute to difficulties in providing tobacco treatment to oncology patients (Toll et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Integrating tobacco treatment into thoracic oncology settings: Lessons learned

et al. 2016

View full text Add to dashboard Cite

Clinical practice guidelines recommend tobacco treatment for all cancer patients. However, little is known about how to integrate tobacco treatment into cancer care. The results of our pilot study of an evidence-based tobacco treatment integrated into a thoracic oncology clinic demonstrated good feasibility and efficacy, providing an opportunity to inform future tobacco treatment integration efforts. Here we describe the process of intervention development, clinic integration, patient identification, and patient enrollment. We report on the intervention content and delivery, patterns of quitting for participants in the tobacco treatment group, and changes in smoking-related psychosocial variables. Clinical implications and suggestions for future research are discussed.

show abstract

Smoking Cessation Assistance for Patients With Bladder Cancer: A National Survey of American Urologists

Cited by 74 publications

References 26 publications

Comprehensive Assessment of the Impact of Cigarette Smoking on Survival of Clear Cell Kidney Cancer

Comprehensive Assessment of the Impact of Cigarette Smoking on Survival of Clear Cell Kidney Cancer

Ethnicity and Smoking Status are Associated with Awareness of Smoking Related Genitourinary Diseases

Integrating tobacco treatment into thoracic oncology settings: Lessons learned

Contact Info

Product

Resources

About